Pinetree Therapeutics Collaborates with AstraZeneca to Develop its Preclinical Candidate
Shots:
- Pinetree Therapeutics has signed an exclusive agreement with AstraZeneca to develop its preclinical EGFR degrader candidate
- As per the agreement, AstraZeneca gets an exclusive option to develop & commercialize the preclinical candidate worldwide. Pinetree is entitled to receive ~$45M upfront & near-term payments as well as additional development & commercial milestones making it a total deal value of ~$500M plus tiered royalties
- The pan-EGFR degrader, designed through the AbReptor antibody platform, exhibited favorable anti-tumor activity across tumors resistant to drug & TKI plus improved activity when combined with current EGFR inhibitors
Ref: Pinetree Therapeutics | Image: Pinetree Therapeutics & AstraZeneca
Related News:- AstraZeneca’s Tagrisso Plus Chemotherapy Receives Health Canada’s Approval to Treat Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
